FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894038307> ?p ?o ?g. }

• W2894038307 endingPage "106" @default.
• W2894038307 startingPage "97" @default.
• W2894038307 abstract "Biosimilar IFX (CT-P13) received marketing approval in Turkey for treatment of rheumatologic diseases, including ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis. Population data on real-world treatment patterns of CT-P13 following marketing approval in European countries are largely unreported. This study examined the prescribing and medication utilization patterns of innovator infliximab (IFX) and CT-P13 in Turkey for patients with RA or IBD naïve to either IFX.Adult patients with ≥1 diagnosis claim for RA or IBD and ≥1 claim for IFX or CT-P13 were identified in the Turkish Ministry of Health database during the following identification periods: 1 Oct 2014-30 May 2015 (RA) and 1 Oct 2014-31 Dec 2015 (IBD). Continuous medical and pharmacy coverage for ≥12 months before and after the date of the first dose (index) IFX or CT-P13 was also required. Separate analyses were done for each population.Seven hundred and seventy nine adult RA and 581 IBD patients met the selection criteria. The majority of RA (74%; n=575) and IBD patients (87%; n=504) were initiated on IFX. The average study observation period was 16 months for the RA and 12 months for the IBD population. Over the observation periods, discontinuation among RA patients occurred in 42% of IFX and 63% of CT-P13 while discontinuation in the IBD cohort occurred in 38% of IFX; and 62% of CT-P13.In this population-based study, more IFX-naïve RA and IBD patients were initially treated with IFX than CT-P13. Discontinuation and switching were observed more often and earlier among patients treated with CT-P13 regardless of disease state. Further studies are needed to understand the reasons for these observed differences." @default.
• W2894038307 created "2018-10-05" @default.
• W2894038307 creator A5002522682 @default.
• W2894038307 creator A5009422030 @default.
• W2894038307 creator A5011438418 @default.
• W2894038307 creator A5020895246 @default.
• W2894038307 creator A5031805494 @default.
• W2894038307 creator A5033380416 @default.
• W2894038307 creator A5043153151 @default.
• W2894038307 creator A5065597314 @default.
• W2894038307 date "2018-10-01" @default.
• W2894038307 modified "2023-10-12" @default.
• W2894038307 title "A descriptive analysis of real-world treatment patterns of innovator (Remicade^®) and biosimilar infliximab in an infliximab-naïve Turkish population" @default.
• W2894038307 cites W1251997985 @default.
• W2894038307 cites W1985763670 @default.
• W2894038307 cites W2007694782 @default.
• W2894038307 cites W2022888597 @default.
• W2894038307 cites W2038535814 @default.
• W2894038307 cites W2053816562 @default.
• W2894038307 cites W2056812338 @default.
• W2894038307 cites W2106152050 @default.
• W2894038307 cites W2110285242 @default.
• W2894038307 cites W2146823681 @default.
• W2894038307 cites W2162768160 @default.
• W2894038307 cites W2171341132 @default.
• W2894038307 cites W2342216265 @default.
• W2894038307 cites W2342464058 @default.
• W2894038307 cites W2410837199 @default.
• W2894038307 cites W2521512376 @default.
• W2894038307 cites W2560455300 @default.
• W2894038307 cites W2574674005 @default.
• W2894038307 cites W2610308940 @default.
• W2894038307 cites W2616615766 @default.
• W2894038307 cites W2971987621 @default.
• W2894038307 doi "https://doi.org/10.2147/btt.s172241" @default.
• W2894038307 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6174299" @default.
• W2894038307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30323555" @default.
• W2894038307 hasPublicationYear "2018" @default.
• W2894038307 type Work @default.
• W2894038307 sameAs 2894038307 @default.
• W2894038307 citedByCount "6" @default.
• W2894038307 countsByYear W28940383072019 @default.
• W2894038307 countsByYear W28940383072020 @default.
• W2894038307 countsByYear W28940383072021 @default.
• W2894038307 countsByYear W28940383072022 @default.
• W2894038307 countsByYear W28940383072023 @default.
• W2894038307 crossrefType "journal-article" @default.
• W2894038307 hasAuthorship W2894038307A5002522682 @default.
• W2894038307 hasAuthorship W2894038307A5009422030 @default.
• W2894038307 hasAuthorship W2894038307A5011438418 @default.
• W2894038307 hasAuthorship W2894038307A5020895246 @default.
• W2894038307 hasAuthorship W2894038307A5031805494 @default.
• W2894038307 hasAuthorship W2894038307A5033380416 @default.
• W2894038307 hasAuthorship W2894038307A5043153151 @default.
• W2894038307 hasAuthorship W2894038307A5065597314 @default.
• W2894038307 hasBestOaLocation W28940383071 @default.
• W2894038307 hasConcept C104863432 @default.
• W2894038307 hasConcept C126322002 @default.
• W2894038307 hasConcept C2776260265 @default.
• W2894038307 hasConcept C2777138892 @default.
• W2894038307 hasConcept C2777402515 @default.
• W2894038307 hasConcept C2777575956 @default.
• W2894038307 hasConcept C2778260677 @default.
• W2894038307 hasConcept C2778715236 @default.
• W2894038307 hasConcept C2779134260 @default.
• W2894038307 hasConcept C2780479503 @default.
• W2894038307 hasConcept C2908647359 @default.
• W2894038307 hasConcept C512399662 @default.
• W2894038307 hasConcept C59491497 @default.
• W2894038307 hasConcept C71924100 @default.
• W2894038307 hasConcept C99454951 @default.
• W2894038307 hasConceptScore W2894038307C104863432 @default.
• W2894038307 hasConceptScore W2894038307C126322002 @default.
• W2894038307 hasConceptScore W2894038307C2776260265 @default.
• W2894038307 hasConceptScore W2894038307C2777138892 @default.
• W2894038307 hasConceptScore W2894038307C2777402515 @default.
• W2894038307 hasConceptScore W2894038307C2777575956 @default.
• W2894038307 hasConceptScore W2894038307C2778260677 @default.
• W2894038307 hasConceptScore W2894038307C2778715236 @default.
• W2894038307 hasConceptScore W2894038307C2779134260 @default.
• W2894038307 hasConceptScore W2894038307C2780479503 @default.
• W2894038307 hasConceptScore W2894038307C2908647359 @default.
• W2894038307 hasConceptScore W2894038307C512399662 @default.
• W2894038307 hasConceptScore W2894038307C59491497 @default.
• W2894038307 hasConceptScore W2894038307C71924100 @default.
• W2894038307 hasConceptScore W2894038307C99454951 @default.
• W2894038307 hasLocation W28940383071 @default.
• W2894038307 hasLocation W28940383072 @default.
• W2894038307 hasLocation W28940383073 @default.
• W2894038307 hasLocation W28940383074 @default.
• W2894038307 hasOpenAccess W2894038307 @default.
• W2894038307 hasPrimaryLocation W28940383071 @default.
• W2894038307 hasRelatedWork W1060061717 @default.
• W2894038307 hasRelatedWork W2157626067 @default.
• W2894038307 hasRelatedWork W2541509819 @default.
• W2894038307 hasRelatedWork W2618207514 @default.
• W2894038307 hasRelatedWork W2946910872 @default.
• W2894038307 hasRelatedWork W3210943096 @default.

• next